Clinical Trials

The Cutaneous Lymphoma Foundation provides information about clinical trials to help move new treatments forward. There may be clinical trials available that we are not aware of. To find additional trials, visit clinicaltrials.gov. Keep in mind that many sponsors of clinical trials cover transportation and other costs for patient participation so we encourage you to consider trials that may not be close to you.

A Dose-Ranging Study of IV BNZ-1

This study is an open-label, multi-center, dose-ranging study to characterize the safety, tolerability, preliminary efficacy, and PK/PD of up to four dose levels of BNZ-1 administered weekly by IV infusion to adults diagnosed with Large Granular Lymphocyte (LGL) Leukemia or refractory Cutaneous T-cell Lymphoma (CTCL).

Naloxone Hydrochloride Study for Relief of Pruritus/Itch

This multi-center, double-blind, vehicle-controlled, randomized crossover design study will evaluate the safety and efficacy of topically applied naloxone lotion, 0.5%, for the treatment of pruritus in patients with the mycosis fungoides (MF) or Sézary syndrome (SS) Forms of Cutaneous T-cell Lymphoma (CTCL).

STUDY OF COBOMARSEN IN PATIENTS WITH MYCOSIS FUNGOIDES (SOLAR)

The main objective of this clinical trial is to study the efficacy and safety of cobomarsen (also known as MRG-106) for the treatment of cutaneous T-cell lymphoma (CTCL), mycosis fungoides (MF) subtype.

Naloxone Hydrochloride Study for Relief of Pruritus/Itch

This multi-center, double-blind, vehicle-controlled, randomized crossover design study will evaluate the safety and efficacy of topically applied naloxone lotion, 0.5%, for the treatment of pruritus in patients with the mycosis fungoides (MF) or Sézary syndrome (SS) Forms of Cutaneous T-cell Lymphoma (CTCL).

STUDY OF COBOMARSEN IN PATIENTS WITH MYCOSIS FUNGOIDES (SOLAR)

The main objective of this clinical trial is to study the efficacy and safety of cobomarsen (also known as MRG-106) for the treatment of cutaneous T-cell lymphoma (CTCL), mycosis fungoides (MF) subtype.

STUDY OF COBOMARSEN IN PATIENTS WITH MYCOSIS FUNGOIDES (SOLAR)

The main objective of this clinical trial is to study the efficacy and safety of cobomarsen (also known as MRG-106) for the treatment of cutaneous T-cell lymphoma (CTCL), mycosis fungoides (MF) subtype.

Trial of Intratumoral Injections of TTI-621

This is a multicenter, open-label, phase 1 study conducted to test intratumoral injections of TTI-621 in subjects that have relapsed and refractory percutaneously accessible solid tumors or mycosis fungoides.

STUDY OF COBOMARSEN IN PATIENTS WITH MYCOSIS FUNGOIDES (SOLAR)

The main objective of this clinical trial is to study the efficacy and safety of cobomarsen (also known as MRG-106) for the treatment of cutaneous T-cell lymphoma (CTCL), mycosis fungoides (MF) subtype.

STUDY OF COBOMARSEN IN PATIENTS WITH MYCOSIS FUNGOIDES (SOLAR)

The main objective of this clinical trial is to study the efficacy and safety of cobomarsen (also known as MRG-106) for the treatment of cutaneous T-cell lymphoma (CTCL), mycosis fungoides (MF) subtype.

STUDY OF COBOMARSEN IN PATIENTS WITH MYCOSIS FUNGOIDES (SOLAR)

The main objective of this clinical trial is to study the efficacy and safety of cobomarsen (also known as MRG-106) for the treatment of cutaneous T-cell lymphoma (CTCL), mycosis fungoides (MF) subtype.

STUDY OF COBOMARSEN IN PATIENTS WITH MYCOSIS FUNGOIDES (SOLAR)

The main objective of this clinical trial is to study the efficacy and safety of cobomarsen (also known as MRG-106) for the treatment of cutaneous T-cell lymphoma (CTCL), mycosis fungoides (MF) subtype.

STUDY OF COBOMARSEN IN PATIENTS WITH MYCOSIS FUNGOIDES (SOLAR)

The main objective of this clinical trial is to study the efficacy and safety of cobomarsen (also known as MRG-106) for the treatment of cutaneous T-cell lymphoma (CTCL), mycosis fungoides (MF) subtype.

Naloxone Hydrochloride Study for Relief of Pruritus/Itch

This multi-center, double-blind, vehicle-controlled, randomized crossover design study will evaluate the safety and efficacy of topically applied naloxone lotion, 0.5%, for the treatment of pruritus in patients with the mycosis fungoides (MF) or Sézary syndrome (SS) Forms of Cutaneous T-cell Lymphoma (CTCL).

Safety and Efficacy Study of a Dual Pi3k Delta/Gamma Inhibitor in T-Cell Lymphoma

The purpose of this study is to evaluate the safety, PK and efficacy of RP6530, a dual PI3K delta/gamma inhibitor in patients with relapsed and refractory T-cell Lymphoma.